Department of General Surgery, Wenzhou People's Hospital, 325000 Wenzhou, Zhejiang, China.
Ann Ital Chir. 2024;95(2):109-118. doi: 10.62713/aic.3155.
To systematically evaluate the efficacy and safety of radiofrequency ablation and liver resection in the therapeutic management of early-stage hepatocellular carcinoma.
We conducted a comprehensive search of domestic and foreign databases including PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), and Wanfang to retrieve literature on radiofrequency ablation and liver resection for the treatment of early hepatocellular carcinoma. The retrieved literature underwent thorough screening, and relevant data were extracted. Following the evaluation of the literature's quality, Meta-analysis was performed using RevMan 5.4 software.
In this study, a total of 11 documents were selected, comprising 1334 patients with hepatocellular carcinoma. Meta-analysis results indicated that there was no statistically significant difference in the 1-year overall survival rate [Relative risk (RR) = 1.01, 95% confidence intervals (CI) (0.98; 1.04)] and the 3-year overall survival rate [RR = 0.95, 95% CI (0.90; 1.01)] between the radiofrequency ablation and liver resection groups (p > 0.05). Similarly, there was no statistically significant difference in the 1-year disease-free survival rate [RR = 0.94, 95% CI (0.87; 1.01)] between the two groups. However, the 3-year disease-free survival rate [RR = 0.84, 95% CI (0.74; 0.96)] of patients in the radiofrequency ablation group was significantly lower than that in the hepatectomy group (p < 0.05). Notably, the incidence of complications [RR = 0.42, 95% CI (0.33; 0.55)] was significantly lower in the radiofrequency ablation group compared to the hepatectomy group. Conversely, the local recurrence rate [RR = 1.45, 95% CI (1.22; 1.73)] was significantly higher in the radiofrequency ablation group compared to the hepatectomy group (p < 0.05).
During the treatment of hepatocellular carcinoma, hepatectomy demonstrates superior clinical efficacy compared to radiofrequency ablation, particularly in its ability to control tumor recurrence. However, radiofrequency ablation presents with fewer complications and a higher level of safety. These findings can serve as a valuable foundation for clinicians when selecting the most suitable treatment approaches for liver cancer.
系统评价射频消融与肝切除术治疗早期肝细胞癌的疗效和安全性。
计算机检索 PubMed、Web of Science、Embase、Cochrane Library、中国知网(CNKI)、万方数据库,收集射频消融与肝切除术治疗早期肝细胞癌的相关文献,按照纳入与排除标准筛选文献、提取资料并评价纳入研究的偏倚风险后,采用 RevMan 5.4 软件进行 Meta 分析。
共纳入 11 篇文献,包括 1334 例肝癌患者。Meta 分析结果显示,两组患者 1 年总生存率[相对危险度(RR)=1.01,95%置信区间(CI)(0.98;1.04)]、3 年总生存率[RR=0.95,95%CI(0.90;1.01)]差异均无统计学意义(P>0.05);两组患者 1 年无瘤生存率[RR=0.94,95%CI(0.87;1.01)]差异亦无统计学意义。但射频消融组患者 3 年无瘤生存率[RR=0.84,95%CI(0.74;0.96)]低于肝切除术组,差异有统计学意义(P<0.05)。射频消融组患者并发症发生率[RR=0.42,95%CI(0.33;0.55)]低于肝切除术组,局部复发率[RR=1.45,95%CI(1.22;1.73)]高于肝切除术组,差异均有统计学意义(P<0.05)。
与射频消融相比,肝切除术治疗肝癌的临床疗效更优,尤其在控制肿瘤复发方面;但射频消融具有并发症少、安全性高的优势。该结论可为临床医师选择肝癌的最佳治疗方案提供参考。